Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Chandra P. Belani"'
Autor:
Sarina Piha-Paul, MD, George Simon, MD, Chandra P. Belani, MD, Heman Chao, PhD, Kim Gaspar, PhD, Brenda Lee, MSc, Afshin Dowlati, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100408- (2022)
Introduction: L-DOS47, a targeted urease–anti-CEACAM6 immunoconjugate, alters the acidity of the tumor microenvironment by increasing local ammonia production. In vitro, the cytotoxic effects of L-DOS47 were additive when combined with pemetrexed a
Externí odkaz:
https://doaj.org/article/b0e5a55630a34b9db3db56cd15ad246c
Autor:
Leonard Joseph Appleman, Marie Pouquet, Ronald G. Stoller, Hussein Tawbi, Sandra Strychor, David R. Gandara, Suresh S. Ramalingam, Alice P. Chen, R. Donald Harvey, Jan H. Beumer, Shannon Puhalla, Taofeek K. Owonikoko, Edward Chu, Yan Lin, Fei Ding, Athanassios Argiris, Brian F. Kiesel, Leigh Swartz, Yixing Jiang, Chandra P. Belani, Daniel P. Petro
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: Veliparib is an oral inhibitor of poly(ADP-ribose) polymerase (PARP)-1 and −2. PARP-1 expression may be increased in cancer, and this increase confers resistance to cytotoxic agents. We aimed to determine the recommended phase 2 dose (RP2D
Autor:
Madhusmita Behera, Camille Ragin, Fadlo R. Khuri, Zhengjia Chen, Rathi N. Pillai, Nabil F. Saba, Sungjin Kim, Chandra P. Belani, Taofeek K. Owonikoko, Suresh S. Ramalingam, Conor E. Steuer
Publikováno v:
Cancer. 122:50-60
BACKGROUND The last 3 decades have witnessed limited therapeutic advances in small cell lung cancer (SCLC) management. This study evaluated real-world trends in the use of systemic therapies and the impact on patient outcomes in the United States. ME
Publikováno v:
Journal of Clinical Oncology. 38:e21680-e21680
e21680 Background: L-DOS47, a cancer therapeutic designed to exploit the acidic tumour extracellular environment, consists of urease conjugated to an anti-CEACAM6 camelid monoclonal antibody. The antibody serves as a targeting agent to deliver urease
Autor:
Athanasios Kotsakis, Suresh S. Ramalingam, Julie R. Brahmer, Pamela A. Hershberger, Daniel P. Petro, Athanassios Argiris, Sanja Dacic, Luis E. Raez, Rodney J. Landreneau, David M. Friedland, Ahmad A. Tarhini, Chandra P. Belani, Roy E. Smith, Dwight E. Heron, Joel S. Greenberger, James D. Luketich
Publikováno v:
Lung Cancer. 81:416-421
Background Cetuximab has demonstrated improved efficacy in combination with chemotherapy and radiotherapy. We evaluated the integration of cetuximab in the combined modality treatment of stage III non-small cell lung cancer (NSCLC). Methods Patients
Autor:
Jong Soon Park, Garth Nicholas, Chandra P. Belani, Eric Sbar, Derek I. Jonker, Catherine Fortin, Ashok Kumar Gupta, Alex A. Adjei, Scott A. Laurie, Laura Q.M. Chow, Steven Zhang, Daniel Patricia, Grace K. Dy
Publikováno v:
Cancer Chemotherapy and Pharmacology. 71:1273-1285
A phase I dose escalation study was performed to determine the maximum tolerated dose (MTD) of intercalated dosing of BMS-690514, a reversible oral panHER/VEGF receptor inhibitor, combined with paclitaxel/carboplatin (PC) in advanced solid tumors. Se
Autor:
Tino Ceschia, Pierina Navarria, Filippo de Marinis, Francesco Grossi, Lucio Buffoni, L. Loreggian, Paal Fr Bruswig, Adolfo Favaretto, Massimo Di Maio, L. Tixi, Luca Boni, Brunello Morrica, Rudolf M. Huber, Giorgio V. Scagliotti, Santi Barbera, C. Caroti, Vito D'Alessandro, Andrea Ardizzoni, Ornella Belvedere, Umberto Ricardi, Andrea Grimaldi, Marcello Tiseo, Diego Cortinovis, Salvatore Parisi, Chandra P. Belani, Tindaro Scolaro
Background Chemo-radiotherapy is standard of care in the treatment of unresectable stage III NSCLC. We aimed at assessing whether the addition of concurrent taxane-chemotherapy to thoracic irradiation following chemotherapy was able to improve treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c04b291665c3f7da1eb9a7bd8379be4f
http://hdl.handle.net/11585/591305
http://hdl.handle.net/11585/591305
Autor:
Beatriz Kanterewicz, Suresh S. Ramalingam, Pamela A. Hershberger, Taofeek K. Owonikoko, Chandra P. Belani, Trent E. Balius
Publikováno v:
International Journal of Cancer. 126:743-755
We observed a 53% response rate in non-small cell lung cancer (NSCLC) patients treated with vorinostat plus paclitaxel/carboplatin in a Phase I trial. Studies were undertaken to investigate the mechanism (s) underlying this activity. Growth inhibitio
Autor:
Chandra P. Belani, David R. Gandara, Igor Espinoza-Delgado, Paul Frankel, Suresh S. Ramalingam, Michael L. Maitland, Barbara J. Gitlitz, Sachdev P. Thomas, Everett E. Vokes, Marianna Koczywas, Athanassios Argiris
Publikováno v:
Journal of Clinical Oncology. 28:56-62
Purpose Vorinostat, a histone deacetylase inhibitor, exerts anticancer effects by both histone and nonhistone–mediated mechanisms. It also enhances the anticancer effects of platinum compounds and taxanes in non–small-cell lung cancer (NSCLC) cel
Autor:
Suresh S, Ramalingam, Robert A, Parise, Ramesh K, Ramanathan, Ramesh K, Ramananthan, Theodore F, Lagattuta, Lori A, Musguire, Ronald G, Stoller, Douglas M, Potter, Athanassios E, Argiris, James A, Zwiebel, Merrill J, Egorin, Chandra P, Belani
Publikováno v:
Clinical Cancer Research. 13:3605-3610
Purpose: The primary objective of this study was to determine the recommended phase II doses of the novel histone deacetylase inhibitor vorinostat when administered in combination with carboplatin and paclitaxel. Experimental Design: Patients (N = 28